BiotechTube
Home/Pipeline/delNS/Prostate Antigens

delNS/Prostate Antigens

Prostate Cancer

PreclinicalActive

Key Facts

Indication
Prostate Cancer
Phase
Preclinical
Status
Active
Company
BlueSky Immunotherapies

About BlueSky Immunotherapies

BlueSky Immunotherapies is a Vienna-based biotech leveraging its novel delNS viral vector platform to develop immunotherapies for cancer and infectious diseases. Its technology is designed to induce potent interferon responses, activating multiple immune cell types and creating a hostile environment for tumors and viruses. The company has advanced its lead HPV-targeted programs into Phase 1/2 clinical trials and has demonstrated compelling proof-of-concept in a veterinary oncology setting, validating the platform's broad potential.

View full company profile

Therapeutic Areas

OncologyInfectious Diseases

Other Prostate Cancer Drugs

DrugCompanyPhase
APVO442Aptevo TherapeuticsPreclinical
APVO452Aptevo TherapeuticsDiscovery
BIO 300Humanetics Corp.Not Specified
OpaganibRedHill BiopharmaPhase 2
MagSense™ PSMA Imaging AgentImagion BiosystemsPre‑clinical
Small-Molecule TherapeuticAIkido LabsPre-clinical
LeronlimabCytoDynPreclinical
CROES RegistryAngioDynamicsPost-Market Registry
Cannabics® PRST-33CNBX PharmaceuticalsDiscovery
HDP-103Heidelberg PharmaPreclinical
ENV105Kairos PharmaPhase 2
AI for Prostate CancerInvenio ImagingResearch